What did we learn from Biogen's CMS slapdown? Data rule

The CMS decision to formally restrict coverage on Aduhelm decisively hammered home the last nail on the Alzheimer’s drug’s commercial coffin. But the muted impact …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

What did we learn from Biogen's CMS slapdown? Data rule

This article is available only to Premium subscribers

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Rare disease biopharma companies weigh in on FDA's new innovation hub

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

What did we learn from Bio­gen's CMS slap­down? Da­ta rule

This article is available only to Premium subscribers

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

What did we learn from Biogen's CMS slapdown? Data rule

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Rare disease biopharma companies weigh in on FDA's new innovation hub

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks